This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

1 week ago 9

Jonathan Ponciano, The Motley Fool

Wed, December 3, 2025 astatine 10:10 AM CST 5 min read

Boston-based MPM BioImpact sold 1.3 cardinal shares of MBX Biosciences worthy an estimated $14.8 cardinal successful the 3rd quarter.
The determination marked a afloat exit for MPM BioImpact, which reported holding nary shares of MBX astatine the extremity of the period.
The presumption antecedently accounted for 2.6% of money assets arsenic of June.
These 10 stocks could mint the adjacent question of millionaires ›

On November 14, MPM BioImpact disclosed successful a Securities and Exchange Commission filing that it sold retired its full involvement successful MBX Biosciences (NASDAQ:MBX), reducing vulnerability by an estimated $14.8 million.

According to a filing with the Securities and Exchange Commission dated November 14, MPM BioImpact sold its full presumption successful MBX Biosciences during the 3rd quarter. The money exited 1,294,416 shares, eliminating its vulnerability and reducing reportable U.S. equity holdings by an estimated $14.8 cardinal based connected quarterly mean pricing.

Top holdings aft the filing:

NASDAQ:MDGL: $46.1 cardinal (7.5% of AUM)
NASDAQ:CGEM: $45.4 cardinal (7.4% of AUM)
NASDAQ:RNA: $33.1 cardinal (5.4% of AUM)
NASDAQ:TRVI: $31.2 cardinal (5.1% of AUM)
NASDAQ:EWTX: $27.9 cardinal (4.6% of AUM)

As of past Wednesday's marketplace close, MBX shares were priced astatine $33.82, up 71% implicit the past twelvemonth and good outperforming the S&P 500, which is up 13% successful the aforesaid period.

Metric

Value

Price (as of marketplace adjacent 11/26/25)	$33.82
Market capitalization	$1.5 billion
Net income (TTM)	($80.5 million)
One-year terms change	71%

MBX Biosciences develops precision peptide therapies targeting endocrine and metabolic disorders, with pb candidates including MBX 2109 for chronic hypoparathyroidism, MBX 1416 for post-bariatric hypoglycemia, and MBX 4291 for obesity and related conditions. The institution operates a clinical-stage biopharmaceutical concern model, generating worth done research, development, and imaginable aboriginal commercialization oregon licensing of proprietary cause candidates. Primary customers are expected to see healthcare providers, endocrinologists, and specialty clinics treating metabolic and endocrine disorders, with an eventual absorption connected patients requiring long-acting hormone therapies.

MBX has been 1 of the much volatile names successful the biotech space, plunging astir 75% from its September 2024 IPO done this March earlier rebounding sharply connected strengthening objective information and renewed capitalist interest. The banal present trades supra its IPO price, reflecting a precise antithetic hazard illustration than it had conscionable months ago.

According to the latest SEC filing, MPM sold each its involvement successful MBX—nearly 1.3 cardinal shares—during the 3rd quarter, an estimated $14.8 cardinal simplification successful a sanction that antecedently represented a meaningful allocation. The steadfast besides exited MoonLake Immunotherapeutics and Crinetics Pharmaceuticals during the aforesaid period, signaling broader repositioning crossed its emerging-biotech exposure.

For its part, MBX continues to beforehand its pipeline: In the 3rd quarter, the institution reported affirmative topline Phase 2 results for canvuparatide successful hypoparathyroidism, completed a $200 cardinal upsized offering, and ended the 4th with $391.7 cardinal successful cash, which the steadfast says is capable to money operations into 2029. CEO Kent Hawryluk highlighted the momentum, noting, “These beardown results enactment our content that canvuparatide has the imaginable to beryllium best-in-class successful hypoparathyroidism, an estimated multibillion-dollar market.” He besides emphasized the drug's upcoming Phase 3 initiation and cardinal 2026 milestones. For semipermanent investors, the connection is clear: MBX is accelerating toward aggregate pivotal catalysts, but its way remains highly data-dependent.